-
labs involved in cutting edge technology, research, and clinical immunotherapeutic programs. Dr. Lior Goldberg’s lab currently has an opening for a Postdoctoral Fellow who will develop chimeric antigen
-
well as disease relapse in order to design novel inhibitors to intervene the malignancies; 3) collaborative analyses of myeloid cancers genomics using high-throughput single-cell technology. The group conducts
-
the Department of Hematological Malignancies Translational Science, Department of Pediatrics, and Gehr Family Center for Leukemia Research. Dr. Li's research program is supported by several NIH (R01s), American
-
labs involved in cutting edge technology, research, and clinical immunotherapeutic programs. Dr. Lior Goldberg’s lab currently has an opening for a Postdoctoral Fellow who will develop chimeric antigen
-
. Present findings at Division meetings and project-specific subgroups regularly. Showcase research at national and international conferences spanning mathematics, biology, and clinical society meetings
-
. Human synthetic insulin, monoclonal antibodies and numerous breakthrough cancer drugs are based on technology developed at the institution. AccessHope™, a subsidiary launched in 2019 serves employers and
-
. Human synthetic insulin, monoclonal antibodies and numerous breakthrough cancer drugs are based on technology developed at the institution. AccessHope™, a subsidiary launched in 2019 serves employers and